Skip to content

SINGLE DOSE ABLATIVE PREOPERATIVE RADIATION TREATMENT FOR EARLY-STAGE BREAST CANCER IN ELDERLY PATIENTS

SINGLE DOSE ABLATIVE PREOPERATIVE RADIATION TREATMENT FOR EARLY-STAGE BREAST CANCER IN ELDERLY PATIENTS - ABLATIVE

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON54805
Enrollment
35
Registered
2014-07-23
Start date
2015-05-11
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Preoperative, single dose, ablative partial breast radiotherapy.

Sponsors

Universitair Medisch Centrum Utrecht
Lead Sponsor

Eligibility

Age
65 Years to 99 Years

Inclusion criteria

Inclusion criteria: • Females at least 50 years of age, with an unifocal cT1N0M0 non-lobular breast cancer on mammogram/ultrasound/MRI and sentinel node biopsy • Females at least 70 years of age, with an unifocal cT1-2(maximum 3 cm)N0M0 non-lobular breast cancer on mammogram/ultrasound/MRI and sentinel node biopsy • Tumor with negative Her2neu receptor and positive estogen receptor • Adequate communication and understanding skills of the Dutch language

Exclusion criteria

Exclusion criteria: • Legal incapacity • BRCA gene mutation. • WHO performance scale > 2. • Previous history of breast cancer • Other type of malignancy within 5 years before breast cancer diagnosis. • Previous history of ipsilateral breast surgery and impaired cosmetic outcome, as assessed by the treating surgeon or radiation-oncologist • Extensive DCIS component. • Invasive lobular carcinoma. • MRI absolute contraindications as defined by the Radiology Department. • Multicentricity or multifocality on MRI. • Nodal or other organ involvement with cytological or histological confirmation. • Treatment with neo-adjuvant chemo- and immunotherapy. . • Indication adjuvant chemo- and immunotherapy (endocrine treatment is allowed).

Design outcomes

Primary

MeasureTime frame
The main objective is to evaluate the pathologic complete response rates following single dose ablative partial breast radiotherapy

Secondary

MeasureTime frame
Secondary endpoints: • Rate of radiological response on MRI. • Quality of life assessment. • Acute- and late-toxicity assessment. • Cosmetic outcome assessment. • Frailty assessment in study population • Local -, regional - and distant relapse rates. • Disease free - and overall survival rates. Tertiary endpoint: • Future research on radiotherapy- associated genotyping.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)